MX2018010414A - Inmunomoduladores. - Google Patents
Inmunomoduladores.Info
- Publication number
- MX2018010414A MX2018010414A MX2018010414A MX2018010414A MX2018010414A MX 2018010414 A MX2018010414 A MX 2018010414A MX 2018010414 A MX2018010414 A MX 2018010414A MX 2018010414 A MX2018010414 A MX 2018010414A MX 2018010414 A MX2018010414 A MX 2018010414A
- Authority
- MX
- Mexico
- Prior art keywords
- protein
- immunomodulators
- amelioration
- inhibit
- useful
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuestos macrocíclicos novedosos que inhiben las interacciones proteína/proteína PD-1/PD-L1 y PD-L1/CD80, y por ende, son útiles para la mejora de distintas enfermedades, que incluyen el cáncer y las enfermedades infecciosas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662303673P | 2016-03-04 | 2016-03-04 | |
PCT/US2017/020304 WO2017151830A1 (en) | 2016-03-04 | 2017-03-02 | Immunomodulators |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018010414A true MX2018010414A (es) | 2018-11-09 |
Family
ID=58347940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018010414A MX2018010414A (es) | 2016-03-04 | 2017-03-02 | Inmunomoduladores. |
Country Status (19)
Country | Link |
---|---|
US (1) | US10143746B2 (es) |
EP (1) | EP3423470B1 (es) |
JP (1) | JP6976263B2 (es) |
KR (1) | KR102409246B1 (es) |
CN (1) | CN109153703B (es) |
AR (1) | AR107802A1 (es) |
AU (1) | AU2017227777B2 (es) |
BR (1) | BR112018017114A2 (es) |
CA (1) | CA3016024A1 (es) |
CL (1) | CL2018002506A1 (es) |
CO (1) | CO2018010316A2 (es) |
EA (1) | EA035134B1 (es) |
ES (1) | ES2886635T3 (es) |
IL (1) | IL261408B (es) |
MX (1) | MX2018010414A (es) |
SG (1) | SG11201807426WA (es) |
TW (1) | TW201734022A (es) |
UY (1) | UY37143A (es) |
WO (1) | WO2017151830A1 (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
US10358463B2 (en) | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
LT3458111T (lt) | 2016-05-19 | 2021-05-25 | Bristol-Myers Squibb Company | Pet vizualizacijos imunomoduliatoriai |
ES2910832T3 (es) * | 2016-11-07 | 2022-05-13 | Bristol Myers Squibb Co | Inmunomoduladores |
EP3642220A1 (en) * | 2017-06-23 | 2020-04-29 | Bristol-Myers Squibb Company | Immunomodulators acting as antagonists of pd-1 |
CN111051332A (zh) * | 2017-10-03 | 2020-04-21 | 百时美施贵宝公司 | 免疫调节剂 |
KR102586510B1 (ko) | 2018-02-13 | 2023-10-12 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
WO2019204609A1 (en) | 2018-04-19 | 2019-10-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
WO2019230919A1 (ja) | 2018-05-31 | 2019-12-05 | 小野薬品工業株式会社 | 免疫チェックポイント阻害薬の有効性判定バイオマーカー |
US20210253614A1 (en) | 2018-05-31 | 2021-08-19 | Peloton Therapeutics, Inc. | Compositions and methods for inhibiting cd73 |
PT3820572T (pt) | 2018-07-13 | 2023-11-10 | Gilead Sciences Inc | Inibidores pd-1/pd-l1 |
TW202028212A (zh) | 2018-10-11 | 2020-08-01 | 日商小野藥品工業股份有限公司 | Sting促效化合物 |
JP7158577B2 (ja) | 2018-10-24 | 2022-10-21 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
EP3946625A1 (en) | 2019-03-28 | 2022-02-09 | Bristol-Myers Squibb Company | Methods of treating tumor |
US20220195046A1 (en) | 2019-03-28 | 2022-06-23 | Bristol-Myers Squibb Company | Methods of treating tumor |
US20220251141A1 (en) * | 2019-05-21 | 2022-08-11 | Bristol-Myers Squibb Company | Immunomodulators |
JP2022534982A (ja) | 2019-05-30 | 2022-08-04 | ブリストル-マイヤーズ スクイブ カンパニー | 細胞局在化シグネチャーおよびその使用 |
WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
WO2020243563A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
AU2020327251A1 (en) | 2019-08-05 | 2022-03-03 | National Cancer Center Japan | Biomarker for accessing efficacy of immune checkpoint inhibitor |
BR112022004316A2 (pt) | 2019-09-22 | 2022-06-21 | Bristol Myers Squibb Co | Caracterização espacial quantitativa para terapia de antagonista lag-3 |
BR112022008191A2 (pt) | 2019-11-08 | 2022-07-12 | Bristol Myers Squibb Co | Terapia com antagonista de lag-3 para melanoma |
WO2021141684A1 (en) * | 2020-01-06 | 2021-07-15 | Bristol-Myers Squibb Company | Immunomodulators |
WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
JPWO2021205631A1 (es) | 2020-04-10 | 2021-10-14 | ||
KR20230058442A (ko) | 2020-08-28 | 2023-05-03 | 브리스톨-마이어스 스큅 컴퍼니 | 간세포성 암종에 대한 lag-3 길항제 요법 |
CN116438199A (zh) | 2020-08-31 | 2023-07-14 | 百时美施贵宝公司 | 细胞定位特征和免疫疗法 |
US20240101666A1 (en) | 2020-10-23 | 2024-03-28 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
CN117858719A (zh) | 2021-03-29 | 2024-04-09 | 朱诺治疗学股份有限公司 | 使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法 |
IL309227A (en) | 2021-10-29 | 2024-02-01 | Bristol Myers Squibb Co | LAG-3 antagonist therapy for hematological cancer |
WO2023147371A1 (en) | 2022-01-26 | 2023-08-03 | Bristol-Myers Squibb Company | Combination therapy for hepatocellular carcinoma |
US20230326022A1 (en) | 2022-04-08 | 2023-10-12 | Bristol-Myers Squibb Company | Machine Learning Identification, Classification, and Quantification of Tertiary Lymphoid Structures |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
US6277818B1 (en) | 1998-10-29 | 2001-08-21 | Angstrom Pharmaceuticals, Inc. | Cyclic peptide ligands that target urokinase plasminogen activator receptor |
AU2003288675B2 (en) | 2002-12-23 | 2010-07-22 | Medimmune Limited | Antibodies against PD-1 and uses therefor |
WO2005079805A1 (en) * | 2004-02-20 | 2005-09-01 | Astrazeneca Ab | Pyrrole derivatives as gonadotropin releasing hormone (gnrh) antagonists |
PT2161336E (pt) | 2005-05-09 | 2013-10-03 | Ono Pharmaceutical Co | Anticorpos monoclonais humanos para morte programada 1 (pd-1) e métodos de tratamento do cancro utilizando anticorpos anti- pd-1 sozinhos ou em combinação com outros agentes imunoterapêuticos¿ |
KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
WO2008117833A1 (ja) | 2007-03-26 | 2008-10-02 | The University Of Tokyo | 環状ペプチド化合物の合成方法 |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
AU2009288289B2 (en) | 2008-08-25 | 2012-11-08 | Amplimmune, Inc. | PD-1 antagonists and methods of use thereof |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
JP5818237B2 (ja) | 2010-09-09 | 2015-11-18 | 国立大学法人 東京大学 | N−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法 |
JP6206943B2 (ja) | 2010-12-03 | 2017-10-04 | 国立大学法人 東京大学 | ペプチドライブラリーの製造方法、ペプチドライブラリー、及びスクリーニング方法 |
US9096642B2 (en) | 2011-06-08 | 2015-08-04 | Aurigene Discovery Technologies Limited | Therapeutic compounds for immunomodulation |
KR20140142736A (ko) * | 2012-03-29 | 2014-12-12 | 오리진 디스커버리 테크놀로지스 리미티드 | 인간의 pd1의 bc 루프로부터의 면역조절 사이클릭 화합물 |
JP2013253842A (ja) | 2012-06-06 | 2013-12-19 | Univ Of Tokyo | pH依存的に標的分子に結合するペプチドのスクリーニング方法 |
SG11201407837WA (en) | 2012-06-06 | 2014-12-30 | Polyphor Ag | Beta-hairpin peptidomimetics |
CN104717974A (zh) * | 2012-06-06 | 2015-06-17 | 比奥诺尔免疫有限公司 | 疫苗 |
ES2761260T3 (es) | 2013-03-15 | 2020-05-19 | Hoffmann La Roche | Biomarcadores y procedimientos de tratamiento de afecciones relacionadas con PD-1 y PD-L1 |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
ES2683356T3 (es) | 2013-09-06 | 2018-09-26 | Aurigene Discovery Technologies Limited | Compuestos peptidomiméticos cíclicos como inmunomoduladores |
WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
US10538555B2 (en) | 2014-09-11 | 2020-01-21 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
US10358463B2 (en) | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
LT3458111T (lt) | 2016-05-19 | 2021-05-25 | Bristol-Myers Squibb Company | Pet vizualizacijos imunomoduliatoriai |
ES2910832T3 (es) | 2016-11-07 | 2022-05-13 | Bristol Myers Squibb Co | Inmunomoduladores |
-
2017
- 2017-03-01 US US15/446,298 patent/US10143746B2/en active Active
- 2017-03-02 KR KR1020187028087A patent/KR102409246B1/ko active IP Right Grant
- 2017-03-02 SG SG11201807426WA patent/SG11201807426WA/en unknown
- 2017-03-02 BR BR112018017114A patent/BR112018017114A2/pt not_active Application Discontinuation
- 2017-03-02 EP EP17711450.1A patent/EP3423470B1/en active Active
- 2017-03-02 ES ES17711450T patent/ES2886635T3/es active Active
- 2017-03-02 AU AU2017227777A patent/AU2017227777B2/en not_active Ceased
- 2017-03-02 EA EA201891879A patent/EA035134B1/ru not_active IP Right Cessation
- 2017-03-02 WO PCT/US2017/020304 patent/WO2017151830A1/en active Application Filing
- 2017-03-02 CN CN201780026544.7A patent/CN109153703B/zh active Active
- 2017-03-02 MX MX2018010414A patent/MX2018010414A/es unknown
- 2017-03-02 JP JP2018546499A patent/JP6976263B2/ja active Active
- 2017-03-02 CA CA3016024A patent/CA3016024A1/en active Pending
- 2017-03-03 UY UY0001037143A patent/UY37143A/es unknown
- 2017-03-03 AR ARP170100541A patent/AR107802A1/es unknown
- 2017-03-03 TW TW106106996A patent/TW201734022A/zh unknown
-
2018
- 2018-08-27 IL IL261408A patent/IL261408B/en unknown
- 2018-09-03 CL CL2018002506A patent/CL2018002506A1/es unknown
- 2018-09-26 CO CONC2018/0010316A patent/CO2018010316A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
US10143746B2 (en) | 2018-12-04 |
IL261408B (en) | 2022-01-01 |
WO2017151830A1 (en) | 2017-09-08 |
CO2018010316A2 (es) | 2018-10-22 |
KR20180118724A (ko) | 2018-10-31 |
EA035134B1 (ru) | 2020-04-30 |
BR112018017114A2 (pt) | 2018-12-26 |
ES2886635T3 (es) | 2021-12-20 |
CL2018002506A1 (es) | 2018-11-09 |
EP3423470A1 (en) | 2019-01-09 |
EP3423470B1 (en) | 2021-08-18 |
SG11201807426WA (en) | 2018-09-27 |
AU2017227777A1 (en) | 2018-10-25 |
IL261408A (en) | 2018-10-31 |
JP6976263B2 (ja) | 2021-12-08 |
CN109153703B (zh) | 2022-09-23 |
AU2017227777B2 (en) | 2021-07-01 |
JP2019512478A (ja) | 2019-05-16 |
UY37143A (es) | 2017-08-31 |
US20170252432A1 (en) | 2017-09-07 |
TW201734022A (zh) | 2017-10-01 |
KR102409246B1 (ko) | 2022-06-14 |
EA201891879A1 (ru) | 2019-02-28 |
CN109153703A (zh) | 2019-01-04 |
CA3016024A1 (en) | 2017-09-08 |
AR107802A1 (es) | 2018-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018010414A (es) | Inmunomoduladores. | |
MX2017011960A (es) | Inmunomoduladores. | |
MX2017010129A (es) | Inmunomoduladores. | |
MX2017007677A (es) | Inmunomoduladores. | |
MX2017004542A (es) | Inmunomoduladores. | |
PH12017500441A1 (en) | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions | |
MX2017008160A (es) | Inmunomoduladores. | |
PH12017500858A1 (en) | Mocrocyclic peptides useful as immunomodulators | |
MX2018012039A (es) | Inhibidores macrociclicos de interacciones proteina/proteina de proteina de muerte programada 1/ligando de muerte programada 1 (pd-1/pd-l1) y cumulo de diferenciacion 80/ ligando de muerte programada 1 (cd80/pd-l1). | |
WO2018085750A3 (en) | Immunomodulators | |
PH12015502027A1 (en) | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1) / pd-l1 protein / protein interactions | |
AU2017319323A8 (en) | Biaryl compounds useful as immunomodulators | |
MX2016013028A (es) | Compuestos utiles como inmunomoduladores. | |
MX2018016038A (es) | Compuestos y metodos para modular la funcion del acido ribonucleico (arn). |